Literature DB >> 15603893

Estimating medical practice expenses from administering adult influenza vaccinations.

Margaret S Coleman1, John Fontanesi, Martin I Meltzer, Abigail Shefer, Daniel B Fishbein, Nancy M Bennett, David Stryker.   

Abstract

Potential business losses incurred vaccinating adults against influenza have not been defined because of a lack of estimates for medical practice costs incurred delivering vaccines. We collected data on vaccination labor time and other associated expenses. We modeled estimates of per-vaccination medical practice business costs associated with delivering adult influenza vaccine in different sized practices. Per-shot costs ranged from USD 13.87 to USD 46.27 (2001 dollars). When compared with average Medicare payments of USD 11.71, per-shot losses ranged from US$ 2.16 to USD 34.56. More research is needed to determine less expensive delivery settings and/or whether third-party payers need to make higher payments for adult vaccinations.

Mesh:

Substances:

Year:  2005        PMID: 15603893     DOI: 10.1016/j.vaccine.2004.07.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011.

Authors: 
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

2.  Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness.

Authors:  Lisa A Prosser; Megan A O'Brien; Noelle-Angelique M Molinari; Katherine H Hohman; Kristin L Nichol; Mark L Messonnier; Tracy A Lieu
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  The National Vaccine Advisory Committee: reducing patient and provider barriers to maternal immunizations: approved by the National Vaccine Advisory Committee on June 11, 2014.

Authors: 
Journal:  Public Health Rep       Date:  2015 Jan-Feb       Impact factor: 2.792

4.  Provider time and costs to vaccinate adult patients: Impact of time counseling without vaccination.

Authors:  Angela Shen; Olga Khavjou; Grant King; Laurel Bates; Fangjun Zhou; Andrew J Leidner; Benjamin Yarnoff
Journal:  Vaccine       Date:  2019-01-11       Impact factor: 3.641

5.  Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.

Authors:  Jay V DePasse; Mary Patricia Nowalk; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman; Shawn T Brown
Journal:  Vaccine       Date:  2017-06-09       Impact factor: 3.641

6.  An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine.

Authors:  Bruce Y Lee; Sarah M Bartsch; Mercy Mvundura; Courtney Jarrahian; Kristina M Zapf; Kathleen Marinan; Angela R Wateska; Bill Snyder; Savitha Swaminathan; Erica Jacoby; James J Norman; Mark R Prausnitz; Darin Zehrung
Journal:  Vaccine       Date:  2015-03-13       Impact factor: 3.641

7.  Cost of universal influenza vaccination of children in pediatric practices.

Authors:  Byung-Kwang Yoo; Peter G Szilagyi; Stanley J Schaffer; Sharon G Humiston; Cynthia M Rand; Christina S Albertin; Phyllis Vincelli; Aaron K Blumkin; Laura P Shone; Margaret S Coleman
Journal:  Pediatrics       Date:  2009-12       Impact factor: 7.124

8.  Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.

Authors:  Lisa A Prosser; Tara A Lavelle; Anthony E Fiore; Carolyn B Bridges; Carrie Reed; Seema Jain; Kelly M Dunham; Martin I Meltzer
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

9.  Billing and payment of commercial and Medicaid health plan adult vaccination claims in Michigan since the Affordable Care Act.

Authors:  Robert M Goodman; Carolyn B Bridges; David Kim; Jamison Pike; Angela Rose; Lisa A Prosser; David W Hutton
Journal:  Vaccine       Date:  2019-10-01       Impact factor: 3.641

10.  Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.

Authors:  Cristina Carias; Carrie Reed; Inkyu K Kim; Ivo M Foppa; Matthew Biggerstaff; Martin I Meltzer; Lyn Finelli; David L Swerdlow
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.